Multiple Myeloma Market to Witness Substantial Growth -- Key Trends and Forecasts of Different Reports for the Next Decade | DelveInsight
Multiple myeloma is a type of cancer characterized by the uncontrolled proliferation of clonal plasma cells, which leads to ...
The Manila Times18h
Alvotech and Dr. Reddy's Announce FDA acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®
"The FDA's filing acceptance of Dr. Reddy's proposed denosumab biosimilar marks an important milestone in bringing this biosimilar medication to more patients throughout the U.S.,” said Milan ...
Alvotech S.A.: Alvotech and Dr. Reddy's Announce FDA acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia and Xgeva
Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; along with its subsidiaries together referred to as "Dr. Reddy's") and Alvotech (NASDAQ: ALVO), a global biotech ...
OmniAb, Inc. (OABI) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Conference Call March 18, 2025 4:30 PM ETCompany ParticipantsKurt Gustafson - Chief Financial OfficerMatt ...
The Tax Adviser17h
Transfer pricing: The C-suite needs to be informed
CEOs need to understand the arm’s-length rules for transactions between commonly controlled entities because of the enormous amounts at stake in tax disputes, financial reporting risk from uncertain ...
Alvotech and Dr. Reddy’s gets FDA nod for Biologic License Application for AVT03
Dr. Reddy’s Laboratories (RDY) and Alvotech (ALVO) announced that the U.S. FDA has accepted a Biologic License Application submission for AVT03. Read more here.
Le Lézard9h
EMPAVELI's Market Success Underscores Growing Demand for Complement Inhibitor Therapies | DelveInsight
DelveInsight's "EMPAVELI Market Size, Forecast, and Market Insight Report" highlights the details around EMPAVELI, a complement inhibitor indicated to treat adult patients with PNH. The report ...
Medscape16h
Diet and Nutrition in Ulcerative Colitis: 5 Things to Know
Ulcerative colitis (UC) is one of the two major types of chronic inflammatory bowel diseases (IBD), along with Crohn’s disease. UC affects the large bowel, has no known cure, and requires lifelong ...
The Manila Times19h
CAMP4 Appoints Multiple Industry Veterans to its Board of Directors
With decades of experience in pharmaceutical development and extensive genetic medicine expertise, Doug E. Williams, Ph.D., and Murray Stewart, DM FRCP, will provide strategic guidance for CAMP4's ...